Enhanced Bone Regeneration in Variable-Type Biphasic Ceramic Phosphate Scaffolds Using rhBMP-2.

Current research in bone regeneration often focuses on scaffolding materials and growth factors. Prior studies have shown that recombinant human bone morphogenetic protein 2 (rhBMP-2) can stimulate bone growth when applied in controlled settings. However, the effectiveness of different scaffold types—such as powder, block, and collagen-enhanced block—remains unclear. No prior work had resolved how scaffold structure interacts with rhBMP-2 concentration to influence bone formation. This gap motivated a study comparing scaffold types and rhBMP-2 dosages in an animal model. Established knowledge includes rhBMP-2's role in osteogenesis, but the specific contribution of scaffold material remains uncertain. This paper's contribution is a direct comparison of scaffold types under controlled rhBMP-2 conditions. The study aimed to clarify how scaffold type and protein concentration affect bone regeneration outcomes. No prior research had tested collagen-enhanced block scaffolds alongside powder and block types in the same model. This work addresses a specific uncertainty in scaffold-based bone regeneration strategies.

The study aimed to evaluate how different scaffold types and rhBMP-2 concentrations influence bone regeneration in a controlled animal model. The specific problem addressed was the lack of clarity regarding scaffold material effects on rhBMP-2 performance. Researchers sought to determine whether scaffold structure could enhance or limit bone formation outcomes. The motivation stemmed from clinical needs for reliable bone graft materials. The study focused on comparing powder, block, and collagen-added block scaffolds. Each scaffold type was tested with two rhBMP-2 concentrations. The goal was to identify which scaffold type and concentration combination best supported osteogenesis. The study also aimed to assess whether higher rhBMP-2 doses always improve bone formation. This work sought to clarify practical guidelines for scaffold and protein use in bone regeneration.

The study used an animal model with 32 rabbits divided into eight groups based on scaffold type and rhBMP-2 concentration. Each group received a specific scaffold and rhBMP-2 dose. Scaffolds were placed in polycarbonate tubes implanted in the bone defect area. The four scaffold types tested were no graft, powder, block, and collagen-added block. Two rhBMP-2 concentrations—0.1 and 0.2 mg/mL—were used in each scaffold group. Bone formation was assessed at 3 and 6 weeks post-implantation. Radiological and histomorphometric analyses were conducted to measure osteogenesis. The study design allowed direct comparisons between scaffold types and protein concentrations. No additional variables were introduced to isolate the effects of scaffold and protein.

Radiological and histomorphometric analyses showed no significant increase in bone formation with higher rhBMP-2 concentrations in any group. The BCP collagen group showed higher bone formation than the powder and block groups at 3 weeks. This effect was observed at both rhBMP-2 concentrations tested. Bone formation was enhanced by rhBMP-2 but reached a plateau with increased concentration. The collagen-added scaffold demonstrated superior early-stage bone formation. No group showed sustained improvement in bone formation at 6 weeks. The powder and block scaffolds did not outperform the collagen-added block. The study found that scaffold structure influenced rhBMP-2 effectiveness. These findings suggest that scaffold type may be more critical than protein concentration.

The authors concluded that scaffold type significantly affects rhBMP-2 performance in bone regeneration. Collagen-added block scaffolds showed greater bone formation than powder and block types at early stages. No group demonstrated increased bone formation with higher rhBMP-2 concentrations. The study suggests that scaffold structure may be more important than protein concentration. The collagen-enhanced scaffold may be useful for initial bone formation. These findings do not support the idea that higher rhBMP-2 doses always improve outcomes. The results imply that scaffold design should be optimized alongside protein application. The authors propose that collagen addition improves early-stage osteogenesis without requiring higher protein doses.